A look back at the biggest devices stories of the decade, in capsule form.

The clinical community has long been searching for a safe and effective surgical alternative to drugs for glaucoma, but the field has moved slowly. A decade ago, non-invasive laser procedures began earning a place as a second-line therapy with limited durability. Invasive surgeries are reserved for end-stage glaucoma because of their complexity, their serious complications, and their high failure rates. Venture firms believe a large, unmet clinical need represents a new $1 billion device market, and the pace of glaucoma device company creation is picking up.